PMID- 26222859
OWN - NLM
STAT- MEDLINE
DCOM- 20151020
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 30
DP  - 2015 Jul
TI  - Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in 
      Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
PG  - e1234
LID - 10.1097/MD.0000000000001234 [doi]
LID - e1234
AB  - In Myanmar, hepatitis C virus (HCV) infection prevalence is 2%. A combination 
      therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a 
      standard treatment, but the effect of this antiviral therapy needs evaluation as 
      to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating 
      patients infected with HCV in Myanmar.This was a retrospective analysis of data 
      from a single clinic exclusively for gastrointestinal diseases in Yangon, 
      Myanmar. We assessed treatment responses at the defined time points and 
      stratified by genotypes of HCV. We also determined incidences of adverse events 
      (AEs). We investigated independent predictors of sustained virologic response 
      (SVR) in the participants.A total of 362 HCV-infected cases were included in this 
      study. The majority were females (51.7%) with mean age of 47.12 years (+/-11.6) and 
      noncirrhosis patients (82%). Rapid virologic response (RVR), early virologic 
      response (EVR), end of treatment response (ETR), and SVR 24 weeks after 
      completion of the dual treatment were 50.3% (178/362), 88% (314/357), 80.1% 
      (286/357), and 85.6% (167/195), respectively. The most frequently reported AEs 
      were nausea/anorexia (72.8%) and flu-like symptoms (62.4%). In multivariate 
      analysis, 4 factors were independently associated with SVR; SVR to genotype 3 
      (odds ratio [OR] 2.4, 95% CI: 1.24-4.62), EVR (OR 0.54, 95% CI: 0.3-0.95), and 
      duration of treatment (OR 1.52, 95% CI: 1.18-1.98). Study limitations were 
      acknowledged.The efficacy and safety of the dual therapy in treating HCV-infected 
      patient in Myanmar was acceptable. We recommend a prospective randomized control 
      trial looking at duration of therapy and rates of achieving SVR, which could 
      significantly impact the care of HCV-infected patients in Myanmar and perhaps 
      other countries as well.
FAU - Naing, Cho
AU  - Naing C
AD  - From the Institute for Research, Development and Innovation (IRDI), International 
      Medical University (IMU), Kuala Lumpur, Malaysia (CN); Option Endoscopy Centre 
      (OEC) Specialist Clinic, Yangon, Myanmar (TS, ATA); and School of Medicine, IMU, 
      Kuala Lumpur, Malaysia (KA).
FAU - Sitt, Than
AU  - Sitt T
FAU - Aung, Aye Td
AU  - Aung AT
FAU - Aung, Kyan
AU  - Aung K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/administration & dosage
MH  - Drug Carriers
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - Hepacivirus/drug effects/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Interferon-alpha/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*administration & dosage
MH  - RNA, Viral/*analysis
MH  - Recombinant Proteins/administration & dosage
MH  - Retrospective Studies
MH  - Ribavirin/*administration & dosage
MH  - Treatment Outcome
MH  - Viral Load/*drug effects
PMC - PMC4554122
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2015/07/30 06:00
MHDA- 2015/10/21 06:00
PMCR- 2015/07/31
CRDT- 2015/07/30 06:00
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2015/10/21 06:00 [medline]
PHST- 2015/07/31 00:00 [pmc-release]
AID - 00005792-201507050-00023 [pii]
AID - 10.1097/MD.0000000000001234 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Jul;94(30):e1234. doi: 10.1097/MD.0000000000001234.